



- (51) **International Patent Classification:**
C12Q 1/68 (2006.01) *G01N 33/52* (2006.01)
- (21) **International Application Number:**
PCT/SG2012/000399
- (22) **International Filing Date:**
23 October 2012 (23.10.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (71) **Applicants:** **DSO NATIONAL LABORATORIES** [SG/SG]; 20 Science Park Drive, Singapore 118230 (SG). **NATIONAL UNIVERSITY OF SINGAPORE** [SG/SG]; 10 Kent Ridge Crescent, Singapore 119260 (SG).
- (72) **Inventors:** **UTTAMCHANDANI, Mahesh**; c/o Defence Medical and Environmental Research Institute, DSO National Laboratories, 27 Medical Drive, Singapore 117510 (SG). **NEO, Jia Ling**; c/o Defence Medical and Environmental Research Institute, DSO National Laboratories, 27 Medical Drive, Singapore 117510 (SG). **KALIDASAN, Kamaladasan, s/o**; c/o National University of Singapore Department of Biology, 10 Kent Ridge Crescent, Singapore 119260 (SG).
- (74) **Agent:** **YUSARN AUDREY**; 24 Raffles Place, #27-01, Clifford Centre, Singapore 048621 (SG).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(54) **Title:** DIRECT VISUAL DETECTION OF NUCLEIC ACID USING GOLD NANOPARTICLES

**Figure 1**

(57) **Abstract:** Gold nanoparticles (AuNPs) are well recognized tools for visual DNA detection. Most reports on its use have however been restricted to synthetic or PCR amplified DNA sequences. Herein, we describe a visual DNA detection method that can detect unamplified genomic DNA sequence specifically, using simple reagents and AuNPs, without the need for PCR. This strategy applies thiolated probes and AuNPs to detect genomic DNA. The thiolated probes, in the presence of target *Salmonella* genomic sequences, cause the AuNPs to aggregate irreversibly, producing a red to purple colourimetric change. As little as 608,000 copies (at 37fM) of the *salmonella* genome were thus detected visually, by eye, without the need for a power source or sophisticated instrumentation. This method thus opens in-roads to direct visual detection, bringing sophisticated DNA analysis capabilities to the point of need.

Direct Visual Detection of Nucleic Acid using Gold Nanoparticles

Field

The invention relates to gold nanoparticles and their use in nucleic acid
5 detection by a visual change.

Background

DNA assays have traditionally been lab-based, primarily because of our
reliance on PCR as the basis for target enrichment and DNA detection.
10 Systems that have been developed for point-of-care DNA detection still
leverage on PCR, and focus on finding ways to make the PCR portable. This
has been achieved through the adoption of sophisticated optics¹, fluidics²,
electrochemical methods³ and thermocycling⁴, which require the consumption
of portable power and reagents that pose issues with thermostability.
15 Nevertheless systems like the Cepheid and R.A.P.I.D. have been developed
for on-site molecular diagnostics of bio-terror agents.⁵ There is a need for a
method and system that can be easily used in any field conditions that is
simple enough for almost anyone to use.

20 Some species of bacteria are pathogenic and can affect the safety of food and
water. Such bacteria include *Vibrio cholerae*, *Salmonella*, and *Escherichia coli*.
V. cholerae causes cholera which often causes epidemics in area struck
by disasters such as floods, tsunamis, earthquake or area where water
sanitation is difficult. In disaster relief situations it is often not possible to move
25 equipment or have access to electricity to conduct tests to determine water or
food safety. *Salmonella* has been responsible for many severe food poisoning
epidemics. Within the US alone it accounted for 129 outbreaks and 3290
human infections annually from the period from 2003 to 2007.⁶ Detection at
the point of care and the capability to monitor the quality control of food-stocks
30 is thus a major concern in food security; especially in an environment where
emergent threats can cause serious concerns, for example the recent shiga-
toxin producing *E.coli* O104:H4 outbreak in Europe.⁷ There is a need for an

easy to use, nucleic acid assay to potentially remove the need to send samples back to a laboratory.

Earlier studies on visual assays reported the use of various techniques such as G-quadruplex⁸⁻¹⁰, molecular beacons^{11, 12}, quantum dots^{13,14} and gold nanoparticles¹⁵⁻¹⁸ to detect the presence of a target nucleotide sequence. Although these methods are effective in detecting synthetic DNA sequences, all require a PCR or an enrichment step. This may be instrument dependent, time-consuming, labour-intensive and as a result delays the reporting of results. An ideal point-of-care nucleic acid assay should be robust and effective, easy to use, and have a small logistic footprint.

Gold nanoparticle (AuNPs) have for the last decade been applied highly effectively as a visual detection tool. These nanoparticles produce a visual readout based on varying inter-particle distance when target reagents are added, providing a capability for sensing. These particles can be coated with DNA or ligands, for target specific detection. When AuNPs are suspended in colloids, well dispersed AuNP appear red. As the inter-particle distance decreases, the plasmon resonance shifts, resulting in the AuNPs appearing purple, violet or blue. In addition, highly aggregated AuNPs precipitate out of the colloid to form black/grey sediments, hence providing a means for biological and chemical sensing.¹⁹⁻²² Pioneering work by Mirkin's group has demonstrated that synthetic DNA sequences can be detected using AuNP decorated with thiolated probes.²³ A variety of assay formats have followed using AuNPs, nearly all of which have applied this technique to the use of synthetic or amplified genomic sequences. Rothberg's group established that single stranded DNA (ssDNA) could adsorb onto AuNP surface whereas, double stranded DNA (dsDNA) are too stable to dissociate and do the same.²⁴

There is a need for a point-of-care nucleic acid assay that is robust and effective, easy to use, with a small logistic footprint.

The present invention seeks to ameliorate at least one of the problems mentioned above.

Summary

Accordingly a first aspect of the invention includes a method of detecting double stranded nucleic acid comprising the steps of:

- 5 a. Making a thiolated probe with complimentary nucleic acid base pairs to a target nucleic acid;
- b. Adding the thiolated probe with a sample suspected of containing the target nucleic acid and a gold nanoparticle wherein a colour change is observed if the sample contains the target nucleic acid.

10

This method may have the advantage of detecting double stranded nucleic acid visually, by the eye, without the need for a power source or sophisticated instrumentation. This method thus opens in-roads to direct visual detection, bringing sophisticated DNA analysis capabilities to the point of need.

15

Another aspect of the invention includes a nucleic acid detection system for visually detecting double stranded nucleic acid comprising a thiolated probe having complimentary nucleic acid base pairs to a target nucleic acid capable of hybridising to a target nucleic acid in a sample suspected of containing the
20 target nucleic acid; and a gold nanoparticle capable of a colour change if the sample contains the target nucleic acid.

Another aspect of the invention includes a device for visually detecting double stranded nucleic acid comprising a first compartment containing a thiolated
25 probe having complimentary nucleic acid base pairs to a target nucleic acid; and a second compartment containing a gold nanoparticle.

Other aspects and advantages of the invention will become apparent to those skilled in the art from a review of the ensuing description, which proceeds with
30 reference to the following illustrative drawings of preferred embodiments.

Brief Description of the Figures

Figure 1. Visual assay for whole genome DNA sensing. The addition of thiolated probes specific to the target gene aggregates AuNPs resulting in a colorimetric change to violet. In the presence of a non-target genomic DNA extract, no visual colour change occurs.

5

Figure 2. Visual readouts for L+R thiolated *invA* probes incubated with genomic DNA and AuNPs. A visual colorimetric change from red to violet was observed only in the tube with *Salmonella* target DNA. The tube containing human DNA and a negative control, with no DNA added, remained red even after prolonged incubation. Absorbance readings at 620nm and 520nm were obtained using a nanodrop spectrophotometer. Error bars refer to standard deviations from 3 independent sets of experiments.

10

Figure 3. Effect of the order of reagent addition on visual output. There is a wide range of responses between the different orders of addition. Best sensitivity was achieved when target DNA was pre-incubated with the probes for 5 minutes before the addition of AuNPs. **A** Order of addition: 1. Target DNA, 2. Probes then 3. Gold Nanoparticles. **B.** Order of addition: 1. Gold Nanoparticles, 2. Probes, then 3. Target DNA. **C.** Order of addition: 1. Gold Nanoparticles, 2. Target DNA, then 3. Probes

15

20

Figure 4. Varying NaCl amounts and its effects on visual output. Effect of increasing salt concentrations. a) Right Probe only. b) Left Probe only. c) No target. c) Profile in a double probe system lacking the target exhibited aggregation of AuNP at final buffer concentration of 423mM of NaCl, after a 1 hour incubation. To be safe, any signals observed over 256mM of NaCl may be considered false positives, under this set of assay conditions. Signals observed in a) and b) at 560mM of NaCl, may be attributed to be false positive results.

25

30

Figure 5. Effect of mutations in probes on visual output. Effect of having mutations in the probes reduced the signal. As long as there is a fully

complementary probe (LP or RP) aggregation seems to occur spontaneously although the visual readout is compromised due to AuNP precipitation as illustrated in the picture taken beyond 5 hours later. Graph depicts A_{620}/A_{520} readings for the final time-point.

5

Figure 6. Effect of using a single probe on visual output. Single probe system is used to compare its effectiveness against the double probe system. The single probe system assays were prepared by incubating the single probe solution with the target genomic DNA extract and adding 0.3M NaCl, 1× PBS, 0.01%SDS to the mixture to make up for the buffer concentration. Despite the absence of another probe, the end-point for aggregation was similar to that of the positive control. Graph depicts A_{620}/A_{520} readings for the final time-point.

10

Figure 7. Effect of having non-target genomic DNA on visual output. Different non-target samples tested under the same set of conditions and Salmonella probes. This demonstrated the specificity and robustness of the probes in being able to detect Salmonella amongst *E. coli* and human genomic DNA extracts (human cell lines obtained from Coriell Laboratories). The final assay concentrations of Salmonella and *E. coli* DNA used were approximately 1ng/μl and human DNA was used at approximately 3 ng/μl.

15

20

Figure 8. TEM Images of gold nanoparticles. The visual assay was performed for a subset of the available targets and probes for Salmonella detection, with the intent to assess the organization patterns of the AuNP clusters using electron microscopy. It was observed that the size of aggregates in TEM varied in a sequence specific manner. Where aggregation did not take place (in the absence of target or in the presence of non-target DNA), the particles were highly diffuse, with no clear aggregation. Aggressive aggregation was observed in the positive control. Where mismatched probes were used, small clusters of particles were observed. Line in the inset SEM images depicts 50nm, 100nm, 50nm, 50nm and 50nm lengths from left to right, respectively.

25

30

Figure 9. The visual assay represents the colorimetric change in each assay with the above combinations of target and probe DNA sequences. The bar chart represents the absorbance ratio: A_{620}/A_{520} which captures the changes in the UV-Vis spectrum. Error bars refers to standard deviations from 3 independent sets of experiments.

Figure 10. A device for visual detection of a target nucleic acid from double stranded nucleic acid showing the step wise use of the device: **A** Opening the device; **B** adding the sample suspected of containing the target nucleic acid to the thiolated probes; **C** removing the nanoparticles from the second compartment; **D** mixing the nanoparticles with the thiolated probes and the sample; and **E** detection of a colorimetric change to violet where the sample contains the target nucleic acid.

Detailed description of preferred embodiments

In attempting to move beyond PCR as the method for target specific double stranded nucleic acid detection, we have herein developed a visual genomic nucleic acid detection system using gold nanoparticles (AuNPs,) and thiolated probes. We modelled this system with a common food-borne pathogen *Salmonella enterica*, by designing probes specific to invasion A gene (invA). A visual, and easy to use, nucleic acid assay can thus contribute greatly to far-forward detection capabilities, potentially by removing the need to send samples back to a laboratory. We have expanded this to include *E. Coli* and *V. cholerae* and it appears that the method and system may be suitable for a wide range of bacteria or any double stranded nucleic acid (dsDNA) such as from other prokaryotic cells, eukaryotic cells, viruses and any other nucleic acid sequences that may need detection.

We hypothesized that dsDNA genomic extracts could be detected sequence specifically by using AuNPs, and designed a series of experiments to optimize conditions that could achieve this outcome (Fig. 1). One would not expect that

dsDNA could be detected in this manner, simply because of the need for genomic nucleic acid to be denatured for optimal hybridization with detection probes. We nevertheless wanted to overcome this, and attempted the assay under ambient room temperatures.

5

In summary, the assay is simple and moderately rapid. It allows both the preparation and detection step to occur at room temperature and does not necessarily need a PCR step. With these advantages, the AuNP-based detection has desirable qualities that can be employed at the point of care, potentially in areas of environmental surveillance and food security.

10

Even though the sensitivity is at the low femtomolar range, which is nowhere near the single molecule sensitivity of PCR, the assay works with simple and readily available agents such as thiolated probes which may be readily designed and synthesized, and AuNP which are all stable and can be stored conveniently. Since power is not required to perform the visual assay, this platform could also be applied broadly during humanitarian assistance and disaster relief operations.

15

Referring to Figure 1 the method of detecting double stranded nucleic acid comprising the steps of; (a) making a thiolated probe 4 with a complimentary nucleic acid base pairs to a target nucleic acid; and (b) adding the thiolated probe 4 with a sample suspected of containing the target nucleic acid 2 and a gold nanoparticle 6 wherein a colour change is the sample contains the target nucleic acid 8. Similarly where the thiolated probe 4 is added to a non-target nucleic acid 10 and a gold nanoparticle 6 and no colour change is observed 12 the sample does not contain the target nucleic acid.

20

25

Preferably the method is conducted without amplification of the nucleic acid; hence the nucleic acid is not amplified or has not been amplified by PCR or other techniques known in the art.

30

Preferably, the incubation is conducted in an ionic solution having an ionic concentration of 400mM or less. More preferably, the incubation is conducted in an ionic solution having an ionic concentration of 250mM or less. In one embodiment the ionic buffer is Sodium Chloride NaCl. The incubation solution
5 may include other buffering or chemical solutions that are known in the art to support a biological system.

Preferably, the gold nanoparticle 6 is added after the thiolated probe 4 has been incubated with a cell suspected of containing the target nucleic acid 2.

10

Preferably, the sample suspected of containing the target nucleic acid 2 is a bacterium, such as *Salmonella*; *Escherichia Coli*; *Bacillus anthracis*; *Vibrio cholera*; or any other bacteria containing double stranded nucleic acid known to be pathogenic in mammals including but not limited to humans, horses,
15 cows, dogs or cats.

Preferably, the target nucleic acid 2 is any double stranded nucleic acid sequence unique to a single species or type. Preferably, the species is a bacterium, such as *Salmonella*; *Escherichia Coli*; *Bacillus anthracis*; *Vibrio cholera*; or any other bacteria known to be pathogenic in mammals including
20 but not limited to humans, horses, cows, dogs or cats.

Preferably, the thiolated probe 4 comprises a complimentary nucleic acid base pair with at least 90% contiguous to a target nucleic acid. In a preferred
25 embodiment the thiolated probe 4 comprises any one of SEQ ID NOS. 1, 2, 3, 4, 9, 14, 15, 12, 13, 16 or 17. The probe can be selected from any one of SEQ ID NOS. 1, 2, 3, 4, 9, 14, 15, 12, 13, 16 and 17.

In one embodiment the method further comprises the step of lysing the cell suspected of containing the target nucleic acid 2 prior to the incubation. . This
30 can be achieved by any method known in the art suitable for lysing cells Such as; Tris-EDTA buffer, chelex-100, 2% SDS and 10% Triton-100; Urea-SDS-

proteinase; 10% SDS, heating at 65°C; Lysozyme (with and without freezing); or Grinding/bead beating or any other established method.

5 The nucleic acid detection system for visually detecting double stranded nucleic acid comprises a thiolated probe 4 having complimentary nucleic acid base pairs to a target nucleic acid 2 capable of hybridising to a target nucleic acid in a sample suspected of containing the target nucleic acid; and a gold nanoparticle 6 capable of a colour change if the sample contains the target nucleic acid. Has the advantage of being able to detect the presence or
10 absence of pathogenic bacteria anywhere just visually by eye without requiring a power source.

The system includes a kit for visually detecting double stranded nucleic acid comprises a thiolated probe 4 having complimentary nucleic acid base pairs
15 to a target nucleic acid 2 capable of hybridising to a target nucleic acid in a sample suspected of containing the target nucleic acid; and a gold nanoparticle 6 capable of a colour change if the sample contains the target nucleic acid.

20 Preferably the thiolated probe of the system is at least 90% contiguous complimentary nucleic acid base pairs to the target nucleic acid. In one embodiment the thiolated probe 4 of the system comprises any one of SEQ ID NOS. 1, 2, 3, 4, 9, 14, 15, 12, 13, 16 or 17. In another embodiment the thiolated probe can be selected from any one of SEQ ID NOS. 1, 2, 3, 4, 9,
25 14, 15, 12, 13, 16 and 17.

Preferably the gold nanoparticle ranges in size from 1nm to 100nm. In a preferred embodiment the gold nanoparticle is about 15 nm. This means that when there is a suspension formed of gold nanoparticles the average size of
30 the gold nanoparticle is 15 nm with the possibility that the suspension includes nanoparticle that range from 10 to 20 nm.

In a preferred embodiment the system may further comprise an ionic solution having an ionic concentration of 400mM or less. In one embodiment the ionic solution of the system has an ionic concentration of 250mM or less.

- 5 In one embodiment the system further comprising a means of cell lysing a cell such as a cell lysing buffer or a mechanical lysing device. Any means known in the art suitable for lysing cells Such as; Tris-EDTA buffer, chelex-100, 2% SDS and 10% Triton-100; Urea-SDS-proteinase; 10% SDS, heating at 65°C; Lysozyme (with and without freezing); or Grinding/bead beating or any other
10 established means of lysing a cell.

The method may be conducted according to any technique or using any device known in the art.

- 15 In one embodiment the method may be conducted using the device depicted in Figure 10. Whereby the device is a modified Ependorf tube comprising a compartment containing a thiolated probe 4 having complimentary nucleic acid base pairs to a target nucleic acid hermetically sealed 16 within the compartment; and a second compartment containing a gold nanoparticle 6.
20 The gold nanoparticle 6 is contained in a compartment within the lid of the ependorf tube. The compartments may be sealed off with parafilm, a suitable polymer or any other material that is suitable to protect the probe 4 and the nanoparticle from perishing or denaturing but is able to be perforated or removed quickly when testing is required.

- 25 Preferably the device for visually detecting double stranded nucleic acid comprises a first compartment containing a thiolated probe having complimentary nucleic acid base pairs to a target nucleic acid; and a second compartment containing a gold nanoparticle.

- 30 Preferably, the thiolated probe 4 of the device comprises a complimentary nucleic acid base pair with at least 90% contiguous to a target nucleic acid. In a preferred embodiment the thiolated probe 4 comprises any one of SEQ ID

NOS. 1, 2, 3, 4, 9, 14, 15, 12, 13, 16 or 17. The probe can be selected from any one of SEQ ID NOS. 1, 2, 3, 4, 9, 14, 15, 12, 13, 16 and 17.

Preferably, the device further comprises a delivery tube 14 suitable for
5 piercing the seal 16; delivering a sample suspected of containing a target nucleic acid 2; delivering an ionic solution having an ionic concentration of 400mM or less; and piercing the second compartment containing the gold nanoparticle 6 such that the gold nanoparticle is able to fall into the compartment containing a thiolated probe 4 and the gold nanoparticle 6 is
10 capable of having a visual colour change in the presence of the target nucleic acid.

The device could easily be adapted to work in a 96 well plate or snap ampoules which allow components to be mixed with the sample suspected of
15 containing a target nucleic acid 2 or any other device which is known in the art that will allow the thiolated probe 4, the sample suspected of containing a target nucleic acid 2 and the gold nanoparticle 6 to be added according the the method described herein.

20 The delivery tube could be any device able to deliver fluid to the system such as a syringe, a pipette or any other suitable means known in the art. Similarly the delivery tube does not need to be capable of piecing a seal as is shown in this embodiment. It would be understood that there could be many other means of opening the seal such as a separate implement for piecing the seal.
25 Alternatively, the seal could be designed for perforation or a peel away detachment or could be a cap.

Nucleic acids

According to the invention there is provided a method system and device for
30 visually detecting a nucleic acid molecule which molecule typically encodes a polypeptide. Specifically the nucleic acid may include DNA molecules; a polynucleotide; a cDNA; an RNA, DNA or a mixed polymer or others

molecules listed below or known in the art. The term embraces a nucleic acid sequence that includes recombinant or cloned DNA isolates and chemically synthesized analogs or analogs biologically synthesized by heterologous systems.

5

"gene sequence," "gene," "nucleic acids" or "polynucleotide" each refer to polynucleotides that are likely to be expressed in a cell suspected of containing the target nucleic acid. The gene sequence is intended to include coding sequences, intervening sequences and regulatory elements controlling transcription and/or translation. The gene sequence is intended to include all allelic variations of the DNA sequence.

10

A nucleic acid or fragment thereof is "substantially homologous" ("or substantially similar") to another if, when optimally aligned (with appropriate nucleotide insertions or deletions) with the other nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 90%, and more preferably at least about 95-98% of the nucleotide bases.

15

Alternatively, substantial homology or (identity) exists when a nucleic acid or fragment thereof will hybridise to another nucleic acid (or a complementary strand thereof) under selective hybridisation conditions, to a strand, or to its complement. Selectivity of hybridisation exists when hybridisation that is substantially more selective than total lack of specificity occurs. Typically, selective hybridisation will occur when there is at least about 87% identity over a stretch of at least about 15 nucleotides, preferably at least about 90%.

20

The length of homology comparison, as described, may be over longer stretches, and in certain embodiments will often be over a stretch of at least about nine nucleotides, usually at least about 15 nucleotides, at least about 20 nucleotides, at least about 30 or more nucleotides.

25

Thus, polynucleotides of the invention preferably have at least 87%, more preferably at least 90% homology to the sequences shown in the sequence listings herein. More preferably there is at least 95%, more preferably at least 98%, homology. Nucleotide homology comparisons may be conducted as

30

known in the art. A preferred sequence comparison program is the GCG Wisconsin Bestfit program.

Nucleotide sequences are preferably at least 15 nucleotides in length, more preferably at least 20, 30, 40, 50, 100 or 200 nucleotides in length.

- 5 Generally, the shorter the length of the polynucleotide, the greater the homology required to obtain selective hybridization. Consequently, where a polynucleotide of the invention consists of less than about 30 nucleotides, it is preferred that the % identity is greater than 90% or 95% compared with the nucleotide sequences for detection.
- 10 Nucleic acid hybridisation will be affected by such conditions as salt concentration, temperature, or organic solvents, in addition to the base composition, length of the complementary strands, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art.
- 15 The "polynucleotide" compositions of this invention include RNA, cDNA, genomic DNA, synthetic forms, and mixed polymers, both sense and antisense strands, and may be chemically or biochemically modified or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those skilled in the art. Such modifications include, for
20 example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.), charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), pendent moieties (e.g.,
25 polypeptides), intercalators (e.g., acridine, psoralen, etc.), chelators, alkylators, and modified linkages (e.g., alpha anomeric nucleic acids, etc.). Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions. Such molecules are known in the art and include, for
30 example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.

cDNA or genomic libraries of various types may be screened as natural sources of the nucleic acids of the present invention.

The nucleic acid sequences used in this invention will usually comprise at least about five codons (15 nucleotides), more usually at least about 7-15
5 codons, and most preferably, at least about 35 codons. One or more introns may also be present. This number of nucleotides is usually about the minimal length required for a successful probe that would hybridize specifically with a target nucleic acid sequence.

As used herein, the terms "gene sequence," and "allele" refer to the double-
10 stranded DNA comprising the gene sequence, allele, or region, comprising the gene sequence, allele or region (i.e. either of the coding and non-coding strands).

As used herein, a "portion" of the gene sequence or region or allele is defined as having a minimal size of at least about eight nucleotides, or preferably
15 about 15 nucleotides, or more preferably at least about 25 nucleotides, and may have a minimal size of at least about 40 nucleotides.

Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or other higher order DNA complexes. The preparation of such probes and suitable hybridisation conditions are well
20 known in the art.

Detectably labeled nucleic acid molecules hybridisable to a DNA molecule of the invention are also provided and include nucleic acid molecules hybridisable to a non-coding region of a nucleic acid, which non-coding region is selected from the group consisting of an intron, a 5' non-coding region, and
25 a 3' non-coding region.

"Probes". Polynucleotide polymorphisms associated with target nucleic acid sequences are detected by hybridisation with a polynucleotide probe which forms a stable hybrid with that of the target sequence, under moderately stringent hybridisation and wash conditions. If it is expected that the probes
30 will be perfectly complementary to the target sequence, stringent conditions

will be used or at least 90% complimentary to the target sequence. Hybridisation stringency may be lessened if some mismatching is expected, for example, if variants are expected with the result that the probe will not be completely complementary.

- 5 Probes for double stranded nucleic acid may be derived from the sequences of the target nucleic acid region or its cDNAs. The probes may be of any suitable length, which span all or a portion of the region and which allow specific hybridisation to the region. If the target sequence contains a sequence identical or 90% similar to that of the probe, the probes may be
- 10 short, e.g., in the range of about 8-30 base pairs, since the hybrid will be relatively stable under even stringent conditions. If some degree of mismatch is expected with the probe, i.e., if it is suspected that the probe will hybridize to a variant region, a longer probe may be employed which hybridises to the target sequence with the requisite specificity. The probes are thiolated.
- 15 Probes comprising synthetic oligonucleotides or other polynucleotides of the present invention may be derived from naturally occurring or recombinant single- or double-stranded polynucleotides, or be chemically synthesized.

A Gold nanoparticle

- A Gold nanoparticle includes a nanoparticle that can reflect colours in a
- 20 detectable manner. Detection may be via spectrophotometry or by eye. Hence a gold nanoparticle may comprise a plurality of gold nanoparticles at a concentration that can be detected for example seen with the eye. Preferably the gold nanoparticle comprises a nanoparticle suspension.

- 'Gold nanoparticles', are sub-micrometer-sized particles typically having
- 25 dimensions ranging from 1-100 nm. Small nanoparticles absorb light in the blue-green portion of the spectrum (~400-500 nm) while red light (~700 nm) is reflected, yielding a deep red colour. As particle size increases, the wavelength of surface plasmon resonance related absorption shifts to longer, redder wavelengths. This means that red light is now adsorbed, and bluer
- 30 light is reflected, yielding particles with a pale blue or purple colour.

Generally, gold nanoparticles are produced in a liquid ("liquid chemical methods") by reduction of chloroauric acid ($\text{H}[\text{AuCl}_4]$), although more advanced and precise methods do exist. After dissolving $\text{H}[\text{AuCl}_4]$, the solution is rapidly stirred while a reducing agent is added. This causes Au^{3+} ions to be reduced to neutral gold atoms. As more and more of these gold atoms form, the solution becomes saturated, and gold gradually starts to precipitate in the form of sub-nanometer particles. The rest of the gold atoms that form stick to the existing particles, and, if the solution is stirred vigorously enough, the particles will be fairly uniform in size.

To prevent the particles from aggregating, some sort of stabilizing agent that sticks to the nanoparticle surface is usually added. They can be functionalized with various organic ligands to create organic-inorganic hybrids with advanced functionality. It can also be synthesised by laser ablation. Other synthesis methods are known in the art. Any gold nanoparticle of less than 100nm would be suitable for use in the method system or device.

Preferably the gold nanoparticle ranges in size from 1nm to 100nm. In a preferred embodiment the gold nanoparticle is about 15 nm. This means that when there is a suspension formed of gold nanoparticles the average size of the gold nanoparticle is 15 nm with the possibility that the suspension includes nanoparticle that range from 10 to 20 nm.

Sample

A "sample", as used herein, refers to an sample that may contain double stranded nucleic acid. Such a sample may include a water sample, a food sample or a biological sample obtained from plants or animals, or from body fluid of an animal including a mammal such as a human. The sample may be a "clinical sample," which is a sample derived from a patient such as a fine needle biopsy sample. A "sample" may also include cells isolated from fluids such as blood, serum, saliva, urine, faeces and the like. Samples can be obtained by methods known to those skilled in the art.

Target nucleic acid

A "target nucleic acid" is from any double stranded nucleic acid of interest such as from prokaryotic cells, eukaryotic cells, viruses and any other nucleic acid sequences that may need detection. Preferably a double stranded nucleic acid that would be of interest to detect would come from a pathogen that may cause infection in a host but it is possible to detect any double stranded nucleic acid, hence, any double stranded nucleic acid could be the target nucleic acid.

Preferably, the target nucleic acid is from a bacterium, such as *Salmonella*; *Escherichia Coli*; *Bacillus anthracis*; *Vibrio cholera*; or any other bacteria containing double stranded nucleic acid known to be pathogenic in mammals including but not limited to humans, horses, cows, dogs or cats. Preferably the target nucleic acid is unique to the genetic code or sequence of a species or a strain or a type or a nucleic acid that is of interest for detection. A probe as described herein is then designed to match a conserved and or unique section of the target nucleic acid.

Examples.

Initially, we started out by attempting to detect double stranded PCR products (data not shown). A region within the invasion (*invA*) gene of *Salmonella enterica* was amplified alongside a region of non-target sequence and a negative control. The products were left to stand with 2 thiolated probes that bound to two contiguous 15bp stretches within the *invA* gene. After the addition of AuNP colloids with average diameters of 15nm, we were able to observe visual readouts for *Salmonella*, through a colorimetric change from red to violet. The negatives and non-target human genomic sequences remained red, as should be expected.

Since a visual differentiation was attainable within a post-PCR format, we wanted to extend this result with genomic DNA detection. Genomic DNA

extracts were left to stand with thiolated probes specific to *Salmonella*. After the addition of AuNPs to each of the mixtures, we were able to observe a visual change with the *Salmonella* genomic DNA (Fig. 2). The negatives which comprised of non-target human sequences and no target did not exhibit a colorimetric change and remained red thus, indicating a possibility of detecting DNA sequences within genomic targets.

We hypothesized that the hybridisation with two probes covering the full 30 bp stretch would produce significantly enhanced signals compared to using each thiolated left (L) and right (R) probe individually that target 15 bp each (*invA*) gene. Hence, we sought to examine how much the signals were compromised by the addition of just single probes. Assays, containing a single probe specific to 30 bp of (*invA*) gene of *Salmonella enterica*, were compared against the positive control which had two probes specific to the target gene. The visual readouts in both one probe and two probes containing assays were rather similar to our surprise, producing sufficiently discernible signals for detection visually, by eye. In the other test conditions, which comprised of non-specific probes, non-targets and no DNA, no colorimetric change was observed. (Fig. 6)

Increasing ionic concentration, for example with the addition of salts such as NaCl, can mask the electrostatic forces between the citrate stabilised AuNPs and mediate aggregation. In order to establish the robustness of the assay, we tested the assay across varying salt concentrations. This was to ensure that truly negative samples did not exhibit any colorimetric change under higher NaCl concentrations in the buffer and thus, result in false positives. Hence, we performed the visual assay under varying concentrations of NaCl, and with different combinations of probes and targets. (Fig. 4) The assays were pictured at three time points to reflect the stability of AuNPs over at least an hour as compared to the positive control in which the AuNPs aggregated within 15 minutes. Interestingly, we found that the negative controls did not aggregate until at least about three times (256 mM) the normal NaCl concentration than that used in our routine assay conditions. This

demonstrates that the assay well-tolerates ionic salt concentrations, and can potentially be deployed under varying concentrations of salt.

Since two out of the three components of the assay were allowed to stand before observing a visual readout, we were curious to find out if the order of addition would have an effect on the visual readout. We performed parallel *Salmonella* genomic DNA concentration dependent assays by pre-mixing two of the three main components at room temperatures, before adding the third reagent to trigger the colour change. This included premixing: 1. genomic DNA, probes; 2. AuNPs, probes; 3. AuNPs, genomic DNA (Fig. 3). In all cases, it was possible to elucidate positive signals, but at different detection thresholds. The best sensitivity was obtained when genomic DNA and probes were allowed to stand before the addition of AuNPs, the sensitivity threshold for the target was at 37fM (data not shown). A weaker sensitivity of 320 fM was observed when AuNPs were allowed to stand with genomic DNA. Another feature that both target and probe concentration dependant profiles revealed was that the increase in visual readout was not a gradual response. Instead, it resembled a sigmoid curve and hinted a transition concentration beyond which the assay would produce a distinct colour change.

Despite being able to detect the *Salmonella* genome in this visual manner, we wanted to ensure that this was no co-incidence and that binding was truly dependent on the designed sequence of our probes. In order to establish the specificity of the probes used so far in the visual *Salmonella* detection mechanism, we designed probes with inherent single and double point-mutations and tested them to pick out the *invA* gene of *Salmonella enterica*. We were expecting to see weaker or no visual readouts from using these probes, when applied in parallel experiments to detect the *Salmonella* genome. The mutant probes were tested in various combinations. After the addition of AuNPs, the visual readouts were compared against the positive control and the negative controls comprising non-targets, non-specific probes and no-target assays (Fig. 5). The presence of a single mis-matched position in the probe did marginally reduce the signal intensities obtained with the

salmonella target. In assays that contained probes with 2 mismatched sequences, there was a significantly reduced colour conversion. These tubes exhibited a negligible colour change, and remained red.

- 5 These mutated probes were also used in a single probe setting (Fig. 6), and produce similar results. In assays that had a probe specific to the *invA* gene, there was visual colorimetric change, whereas in the probes increasing numbers of point-mutations significantly changed the visual output.
- 10 Furthermore, in order to test the specificity of the probes to the genomes of choice, they we tested against various different genomic DNA samples (*Escherichia coli* and Human genome samples). Upon addition of AuNPs, only samples with Salmonella DNA present displayed a violet colouration, all other tubes containing non-target DNA sequences remained red (Fig. 7). In
- 15 addition, we tested a separate set of thiolated probes designed to detect *Bacillus anthracis*. Under the same set of test conditions, no colour change was exhibited when they were tested with Salmonella DNA, demonstrating the requirement of probe specificity (Fig 5).
- 20 In addition, we performed TEM experiments to image the aggregation profiles of these AuNPs with varying probes and targets. Intense clustering of AuNPs were observed with the positive controls, with relatively smaller clusters observed with mis-matched probes (Fig 8). As expected no observable clusters were observed in the absence of target or with human genomic
- 25 target, it was also determined that probe thiolation was critical to visual detection. Probes with the Salmonella targeting sequence but without the thiol group produced no visual readouts (data not shown). This indicated the importance of the probe interactions to the gold AuNP for production of the visual colour change.
- 30 To investigate the underlying mechanism further, we performed gel retardation experiments, to determine the interaction sequence and to further understand the need for ordered addition of the reagents, for optimal visual

output. Taken together, these results indicate that the salmonella probes independently complex with the double stranded target sequences. The thiol groups on the probes then mediate the interaction with the AuNPs, resulting in the observed aggregation and the colour change.

5

With these results, we have demonstrated the ability to detect Salmonella genomic DNA extracts visually using AuNPs. This may be the first report that establishes the utility of gold nanoparticles to detect genomic DNA sequence specifically, without the need for PCR. This in itself is a significant milestone that can be capitalized on in the field of visual DNA detection.

10

Next we extended the panel of genomic DNA targets to be assayed and integrate the DNA extraction step to this visual detection system with *E. coli*. This will significantly accelerate the capability to detect double-stranded DNA, sequence specifically, outside a laboratory environment.

15

For *E. coli* it was first necessary to lyse the target cell prior to incubation with the thiolated probe. This can be achieved by any method known in the art suitable for lysing cells. The following methods and reagents may be considered for bacterial genomic DNA extraction for the visual DNA assay with gold nanoparticles:

20

25

- 1) Tris-EDTA buffer, chelex-100, 2% SDS and 10% Triton-100
- 2) Urea-SDS-proteinase
- 3) 10% SDS, heating at 65°C
- 4) Lysozyme (with and without freezing)
- 5) Grinding/bead beating

30

Materials and equipments. Autoclaved MilliQ water was used for all buffers, stock solutions of oligonucleotides. Oligonucleotides were synthesised by local manufacturers (Suprenom Pte. Ltd.) with standard HPLC purification (Table 1). Thiolated probe sequences and *Bacillus anthracis* sequences were purchased from Suprenom Pte. Ltd. The Salmonella probe sequences were

purchased from 1st Base Primers Pte. Ltd. All genomic DNA samples were extracted using the Qiagen DNA extraction kit. Aqueous solutions of 15nm diameter gold nanoparticles were purchased from Ted Pella (mean diameter listed by the manufacturer). Absorbance readings were obtained from an ND-1000 spectrophotometer.

Salmonella enterica target amplification: A 10 μ L PCR reaction was prepared using 9 ng of genomic DNA with 1.5mM MgCl₂, 1x PCR Buffer, 0.3 μ M Salmonella forward and reverse primers, with 0.5 units of AmpliTaq Gold DNA polymerase (Applied Biosystems). Cycling conditions included an initial denaturation at 95°C for 3 mins, followed by 34 cycles of 95°C 1min, 53°C 1min, 72°C 1min.

Non-target control amplification: An 85bp Emilin1 gene segment from human genomic DNA was amplified. A 10 μ L PCR reaction was prepared using 10 ng of HapMap Genomic DNA sample (extracted from immortalized cell lines, Cat. No: GM7034, Corriell Laboratories) with 1.5mM MgCl₂, 1x PCR buffer, 0.3 μ M forward and reverse primers and 0.5 units of AmpliTaq Gold DNA polymerase (Applied Biosystems). Cycling conditions included an initial denaturation at 95°C for 3 mins, followed by 34 cycles of 95°C 1min, 63°C 1min, 72°C 1min.

Probe preparation: Protected 5' thiolated end of oligonucleotide probes (3nmoles) were deprotected in 0.1M DTT (final concentration) and purified on size exclusion NAP-5 sephadex spin columns (Amersham, GE Healthcare). The oligonucleotides were left to stand in 0.3M NaCl, 1 $\times$ PBS. Then, aqueous 10% SDS, was added to the solution (final concentration: 0.01%). These oligonucleotides were used as probes in the visual assay.

Genome copy number calculation: The Salmonella enterica genome was approximated to be 5Mbp (UCSC Genome Browser). 3.28ng was added to a 27 μ L reaction, which corresponded to a concentration of 37fM. The average molecular weight of a base pair was assumed to be 650gmol⁻¹. Thus, the number of copies of genomic DNA for 3.28 ng of genomic DNA was

calculated to be $(3.28 \times 10^{-9} \text{g} \times 6.022 \times 10^{23} \text{mol}^{-1}) / (5 \times 10^6 \text{bps} \times 650 \text{gmol}^{-1} \text{bp}^{-1}) = 608$ thousand copies.

Genomic material: Human genomic DNA was obtained from commercial immortalized human B-Lymphocyte cell lines (Corriell Laboratories), and cultured according to vendor's protocol. The genomic DNA was extracted from the cells using Puregene Cell and Tissue kit (Gentra Systems).

TEM Imaging: Drops of colloidal suspension were placed onto carbon coated copper grids and left to dry under a lamp. The copper grids were then analysed on a JEOL JEM 2010F HRTEM with an accelerating voltage of 200keV.

Table 1. Probes, primers and target sequences used in the study. The sizes of the resulting amplicons were 119bp for *invA* segment in salmonella DNA and 50bp for the *Emilin1* segment in human DNA.

SEQ ID NO.		SEQUENCE
1	Salmonella <i>invA</i> gene Left Probe sequence (L)	5'HS-(CH ₂) ₆ -[T] ₂₀ -GCC-AGT-ACG-ATA-TTC-3'
2	Salmonella <i>invA</i> gene Right Probe sequence (R)	5'HS-(CH ₂) ₆ -[T] ₂₀ -ATA-AAC-ACC-AAT-ATC-3'
3	Salmonella <i>invA</i> gene Left Mutated Probe sequence (LM1) (mutated base is <u>underlined</u>)	5'HS-(CH ₂) ₆ -[T] ₂₀ -GCC-AGT-AT <u>G</u> -ATA-TTC-3'
4	Salmonella <i>invA</i> gene Right Mutated Probe sequence (RM1) (mutated base is <u>underlined</u>)	5'HS-(CH ₂) ₆ -[T] ₂₀ -ATA-AAC-AT <u>C</u> -AAT-ATC-3'
5	Salmonella <i>invA</i> gene Left Double Mutated Probe sequence (LM2) (mutated bases is <u>underlined</u>)	5'HS-(CH ₂) ₆ -[T] ₂₀ -GCT <u>T</u> -G <u>G</u> T-ACG-ATA-TTC-3'
6	Salmonella <i>invA</i> gene Right Double Mutated Probe sequence (RM2) (mutated bases is <u>underlined</u>)	5'HS-(CH ₂) ₆ -[T] ₂₀ -ATA-AAC-ACC-AAC-G <u>T</u> C-3'
7	Salmonella <i>invA</i> gene Forward Primer	5'-CCTGATCGCACTGAATATCG-3'
8	Salmonella <i>invA</i> gene Reverse Primer	5'-AACGACCCCATAAACACCAA-3'

9	Salmonella target sequence within the InvA gene (Segments in <u>underlined</u> targeted by the L-probe, Segments in <i>italics</i> targeted by the R probe)	5'- GAATATCGTACTGGCGATATTGG TGTTTAT-3'
10	Non-target <i>Emilin1</i> Forward Primer	5'- TCTGCTGAGGCTCTCCTGTT-3'
11	Non-target <i>Emilin1</i> Reverse Primer	5'- CTGCTTTGAAGTCCACGTAGC-3'
12	<i>Bacillus anthracis</i> Left Probe sequence	5'HS-(CH ₂) ₆ -[T] ₂₀ -TAA-CAA-TAA-TCC-CTC-3'
13	<i>Bacillus anthracis</i> Right Probe sequence	5'HS-(CH ₂) ₆ -[T] ₂₀ -ATC-CTT-ATC-AAT-ATT-3'
14	<i>Escherichia Coli</i> Left Probe sequence	5'HS-(CH ₂) ₆ -[T] ₂₀ -ATC-ACG-CAG-GTT-GGC-3'
15	<i>Escherichia Coli</i> Right Probe sequence	5'HS-(CH ₂) ₆ -[T] ₂₀ -AAC-CAG-ACG-ATA-GTT-3'
16	<i>Vibrio cholerae</i> Left Probe sequence	5'- HS-(CH ₂) ₆ -[T] ₂₀ -CCA-CCT-ACC-TTT-ATG-GTC-C-3'
17	<i>Vibrio cholerae</i> Right Probe sequence	5'- HS-(CH ₂) ₆ -[T] ₂₀ -GGT-TTG-TCG-AAT-TAG-CTT-CAC-C-3'

Visual Assay. The final assay of 27 μ l contained a buffer comprising 90mM NaCl, 0.2X PBS, 0.002% SDS, pH 7.0, 320fM of Salmonella genomic DNA extract, 2.1nM each for Salmonella probe sequences and 1.6nM of 15nm AuNPs. 3 μ l of both probes with 20nM in buffer (0.3M NaCl, 1 $\times$ PBS, pH 7.0 and 0.01% SDS) was left to stand with 1 μ l of genomic DNA extract (9pM) for 5 minutes. 20 μ l of AuNPs at a stock concentration of 2.8 $\times 10^{10}$ particles per ml (Ted Pella) was added to the mixture and allowed to stand for about 15 minutes. The absorbance readings were taken typically 15 minutes after adding the AuNPs. After prolonged standing, the AuNPs in the positive control precipitated and started to form black/grey sediments in the tubes. The tubes were photographed using a Samsung (ST50) digital camera 12.2 mega-pixel.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. The invention includes all such variation and modifications. The invention also includes all of the steps, features, formulations and compounds

referred to or indicated in the specification, individually or collectively and any and all combinations or any two or more of the steps or features.

Each document, reference, patent application or patent cited in this text is
5 expressly incorporated herein in their entirety by reference, which means that it should be read and considered by the reader as part of this text. That the document, reference, patent application or patent cited in this text is not repeated in this text is merely for reasons of conciseness.

10 Any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention.

15 The present invention is not to be limited in scope by any of the specific embodiments described herein. These embodiments are intended for the purpose of exemplification only. Functionally equivalent products, formulations and methods are clearly within the scope of the invention as described herein.

20 The invention described herein may include one or more range of values (e.g. size, concentration etc). A range of values will be understood to include all values within the range, including the values defining the range, and values adjacent to the range which lead to the same or substantially the same
25 outcome as the values immediately adjacent to that value which defines the boundary to the range.

Throughout this specification, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising", will be
30 understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. It is also noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as "comprises", "comprised", "comprising" and the like can have the meaning

attributed to it in U.S. Patent law; e.g., they can mean "includes", "included",
"including", and the like; and that terms such as "consisting essentially of" and
"consists essentially of" have the meaning ascribed to them in U.S. Patent
law, e.g., they allow for elements not explicitly recited, but exclude elements
5 that are found in the prior art or that affect a basic or novel characteristic of
the invention.

Other definitions for selected terms used herein may be found within the
detailed description of the invention and apply throughout. Unless otherwise
10 defined, all other scientific and technical terms used herein have the same
meaning as commonly understood to one of ordinary skill in the art to which
the invention belongs.

References

1. F. B. Myers and L. P. Lee, *Lab on a chip*, 2008, **8**, 2015-2031.
2. J. Mairhofer, K. Roppert and P. Ertl, *Sensors*, 2009, **9**, 4804-4823.
3. M. G. H. T Gregory Drummond, Jacqueline K Barton, *Nature Biotechnology*, 2003, **21**, 1192-1199.
4. H. L. a. L. J. Rothberg, *American Chemical Society*, 2004, **126**, 10958-10961.
5. D. A. Martin Jones, Salvatore Marras, Hiyam El-Hajj, Michael T. Taylor and William McMillan, *Clinical Chemistry*, 2001, **47**, 1917-1918.
6. A. L. N. L. Hannah Gould, Karen M. Herman, Dana J. Cole, Ian T. Williams, Barbara E. Mahon, Patricia M. Griffin, *Morbidity and Mortality Weekly Report*, 2011, **60**, 1197-1202.
7. D. A. Rasko, D. R. Webster, J. W. Sahl, A. Bashir, N. Boisen, F. Scheutz, E. E. Paxinos, R. Sebra, C.-S. Chin, D. Iliopoulos, A. Klammer, P. Peluso, L. Lee, A. O. Kislyuk, J. Bullard, A. Kasarskis, S. Wang, J. Eid, D. Rank, J. C. Redman, S. R. Steyert, J. Frimodt-Møller, C. Struve, A. M. Petersen, K. A. Krogfelt, J. P. Nataro, E. E. Schadt and M. K. Waldor, *New England Journal of Medicine*, 2011, **365**, 709-717.
8. Neo. J. L. Uttamchandani Mahesh, Aw Kang Lie Darius, *Molecular Biosystems*, 2010, **6**, 1-3.
9. J. L. Neo, K. D. Aw and M. Uttamchandani, *Analyst*, 2011, **136**, 1569-1572.
10. S. Zhang, Z. S. Wu, L. Qiu, H. Zhou, G. Shen and R. Yu, *Chemical communications*, 2010, **46**, 3381-3383.
11. S. Song, Z. Liang, J. Zhang, L. Wang, G. Li and C. Fan, *Angewandte Chemie International Edition*, 2009, **48**, 8670-8674.
12. T. N. Grossmann, L. Röglin and O. Seitz, *Angewandte Chemie International Edition*, 2007, **46**, 5223-5225.
13. C.-Y. Zhang, H.-C. Yeh, M. T. Kuroki and T.-H. Wang, *Nat Mater*, 2005, **4**, 826-831.

14. C.-y. Zhang and J. Hu, *Analytical Chemistry*, 2010, **82**, 1921-1927.
15. R. L. L. Chad A. Mirkin, Robert C. Mucic and James J. Storhoff, *Nature*, 1996, **382**, 607-609.
16. A. D. L. James J Storhoff, Viswanadham Garimella, Y Paul Bao, and Uwe R Müller, *Nat Biotechnol*, 2004, **22**, 883-887.
17. R. J. Y. Charles Cao, C. Shad Thaxton, Chad A. Mirkin, *Talanta*, 2005, **67**, 449-455.
18. C. J. Ye Lim Jung, Harshala Parab, Taihua Li, Hyun Gyu Park, *Biosensors and Bioelectronics*, 2010, **25**, 1941-1946.
19. H. Wei, B. Li, J. Li, E. Wang and S. Dong, *Chemical communications*, 2007, 3735-3737.
20. L. Wang, X. Liu, X. Hu, S. Song and C. Fan, *Chemical communications*, 2006, 3780-3782.
21. C. Yang, Y. Wang, J. L. Marty and X. Yang, *Biosensors & bioelectronics*, 2011, **26**, 2724-2727.
22. L. Sun, Z. Zhang, S. Wang, J. Zhang, H. Li, L. Ren, J. Weng and Q. Zhang, *Nanoscale Research Letters*, 2008, **4**, 216-220.
23. C. A. M. Robert A. Reynolds, Robert L. Letsinger, *American Chemical Society*, 2000, **122**, 3795-3796.
24. H. Li and L. Rothberg, *Proceedings of the National Academy of Sciences of the United States of America*, 2004, **101**, 14036-14039.
25. J. Yang, B. K. Pong, J. Y. Lee and H. P. Too, *Journal of inorganic biochemistry*, 2007, **101**, 824-830.
26. D. Peled, R. Naaman and S. S. Daube, *The Journal of Physical Chemistry B*, 2010, **114**, 8581-8584.
27. J. Yang, J. Y. Lee, H.-P. Too and G.-M. Chow, *Biophysical Chemistry*, 2006, **120**, 87-95.



Claims:

1. A method of detecting double stranded nucleic acid comprising the steps of;
 - a. Making a thiolated probe with complimentary nucleic acid base pairs to a target nucleic acid;
 - b. Adding the thiolated probe with a sample suspected of containing the target nucleic acid and a gold nanoparticle wherein a colour change is observed if the sample contains the target nucleic acid.
2. The method of claim 1 wherein the double stranded nucleic acid is not amplified.
3. The method of claim 1 wherein the thiolated probe comprises at least 90% contiguous complimentary nucleic acid base pairs to the target nucleic acid
4. The method of claim 1 wherein the gold nanoparticle is added after the thiolated probe has been added to the sample suspected of containing the target nucleic acid.
5. The method of claim 1 wherein the incubation is in an ionic solution having an ionic concentration of 400mM or less.
6. The method of claim 1 wherein the incubation is in an ionic solution having an ionic concentration of 250mM or less.
7. The method of claim 1 wherein the gold nanoparticle ranges in size from 1nm to 100 nm
8. The method of claim 1 wherein the gold nanoparticle is about 15 nm
9. The method of claim 1 wherein the sample suspected of containing the target nucleic acid is a bacterium.
10. The method of claim 8 wherein the bacterium is a *Salmonella*.
11. The method of claim 9 wherein the thiolated probe comprises SEQ ID NOS. 1, 2, 3, 4, or 9.
12. The method of claim 8 wherein the bacterium is a *Escherichia Coli*.
13. The method of claim 11 wherein the thiolated probe comprises SEQ ID NOS. 14, or 15.
14. The method of claim 8 wherein the bacterium is a *Bacillus anthracis*.

15. The method of claim 13 wherein the thiolated probe comprises SEQ ID NOS. 12 or 13.
16. The method of claim 8 wherein the bacterium is a *Vibrio cholera*.
17. The method of claim 15 wherein the thiolated probe comprises SEQ ID NOS. 16 or 17.
18. The method of claim 1 further comprising the step of lysing a cell in the sample suspected of containing the target nucleic acid prior to adding the thiolated probe.
19. A nucleic acid detection system for visually detecting double stranded nucleic acid comprising a thiolated probe having complimentary nucleic acid base pairs to a target nucleic acid capable of hybridising to a target nucleic acid in a sample suspected of containing the target nucleic acid; and a gold nanoparticle capable of a colour change if the sample contains the target nucleic acid.
20. The system of claim 19 wherein the double stranded nucleic acid is not amplified.
21. The system of claim 19 wherein the thiolated probe comprises at least 90% contiguous complimentary nucleic acid base pairs to the target nucleic acid.
22. The system of claim 19 further comprising an ionic solution having an ionic concentration of 400mM or less.
23. The system of claim 19 further comprising an ionic solution having an ionic concentration of 250mM or less.
24. The system of claim 19 wherein the gold nanoparticle ranges in size from 1nm to 100 nm
25. The system of claim 19 wherein the gold nanoparticle is about 15 nm
26. The system of claim 19 wherein the double stranded nucleic acid to be detected is from a bacterium.
27. The system of claim 26 wherein the bacterium is a *Salmonella*.
28. The system of claim 26 wherein the bacterium is a *Escherichia Coli*.
29. The system of claim 26 wherein the bacterium is a *Bacillus anthracis*.
30. The system of claim 26 wherein the bacterium is a *Vibrio cholera*.

31. The system of claim 19 or 27 wherein the thiolated probe comprises SEQ ID NOS. 14, or 15.
32. The system of claim 19 or 28 wherein the thiolated probe comprises SEQ ID NOS. 12 or 13.
33. The system of claim 19 or 26 wherein the thiolated probe comprises SEQ ID NOS. 1, 2, 3, 4, or 9.
34. The system of claim 19 or 30 wherein the thiolated probe comprises SEQ ID NOS. 16 or 17.
35. The system of claim 19 further comprising a means of lysing a cell.
36. A device for visually detecting double stranded nucleic acid comprising a first compartment containing a thiolated probe having complimentary nucleic acid base pairs to a target nucleic acid; and a second compartment containing a gold nanoparticle.
37. A device of claim 36 further comprising a means of adding a sample suspected of containing a target nucleic acid to the first compartment and a means of moving the nanoparticles from the second compartment to the first compartment for visually detecting the double stranded nucleic acid.
38. The device of claim 36 further comprising a delivery tube suitable for delivering a fluid sample suspected of containing a target nucleic acid; and delivering an ionic solution having an ionic concentration of 400mM or less; such that the gold nanoparticle when combined in the compartment containing a thiolated probe is capable of having a visual colour change in the presence of the target nucleic acid.
39. The device of claim 36 wherein the thiolated probe comprises at least 90% contiguous complimentary nucleic acid base pairs to the target nucleic acid.
40. The device of claim 36 further comprising an ionic solution having an ionic concentration of 400mM or less.
41. The device of claim 36 further comprising an ionic solution having an ionic concentration of 250mM or less.
42. The device of claim 36, wherein the gold nanoparticle ranges in size from 1nm to 100 nm


- 43. The device of claim 36 wherein the gold nanoparticle is about 15 nm
- 44. The device of claim 36, wherein the thiolated probe comprises SEQ ID NOS. 14, or 15.
- 45. The device of claim 36, wherein the thiolated probe comprises SEQ ID NOS. 12 or 13.
- 46. The device of claim 36, wherein the thiolated probe comprises SEQ ID NOS. 1, 2, 3, 4, or 9.
- 47. The device of claim 36, wherein the thiolated probe comprises SEQ ID NOS. 16 or 17.
- 48. The device of claim 36 further comprising a means of lysing a cell.

**Figure 1****Figure 2**


2/10

Figure 3


A



B.




C.



3/10

Figure 4



4/10

C.






Figure 4.

5/10

A





B

Figure 5.

6/10

A




B

Figure 6.

7/10

A.



B.




Figure 7.




Figure 8.

9/10

Salmonella Thiolated probes	-	-	-	+	+	+
Salmonella Genomic DNA	-	-	+	-	-	+
Human Genomic DNA	-	+	-	-	+	-
E.coli Thiolated Probes	+	+	+	-	-	-
E.coli Genomic DNA	+	-	-	+	-	-
Gold Nanoparticles (15nm)	+	+	+	+	+	+

Visual Signal (A_{620}/A_{520})

After 15 min





Figure 9

10/10

Figure 10



INTERNATIONAL SEARCH REPORT

International application No.

PCT/SG2012/000399

A. CLASSIFICATION OF SUBJECT MATTER

C12Q 1/68 (2006.01) G01N 33/52 (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EPODOC, MEDLINE, HCAPLUS, BIOSIS & keywords: nanoparticle, gold, DNA, double stranded, thiolated, visually, detect and like terms; GENOMEQUEST: SEQ ID NOS: 1-4, 9, 12-17

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	Documents are listed in the continuation of Box C	

☒ Further documents are listed in the continuation of Box C☒ See patent family annex

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
18 December 2012Date of mailing of the international search report
18 December 2012

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
Email address: pct@ipaustalia.gov.au
Facsimile No.: +61 2 6283 7999

Authorised officer

Richard Filmer
AUSTRALIAN PATENT OFFICE
(ISO 9001 Quality Certified Service)
Telephone No. 0262832735

INTERNATIONAL SEARCH REPORT		International application No.
C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		PCT/SG2012/000399
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2001/073123 A2 (NANOSPHERE INC.) 04 October 2001 Summary of Invention; Example 14; page 54 lines 8-10, page 59 lines 13-29, pg 100 lines 8-11	1-10, 12, 14, 16, 18-30, 35-43, 48
Y	Summary of Invention; Example 14; page 54 lines 8-10, page 59 lines 13-29, pg 100 lines 8-11	11, 13, 15, 17, 31-34, 44-47
X	WO 2008/135929 A2 (STABVIDA, INVESTIGACAO A SERVICOS EM CIENCIAS BIOLOGICAS, LDA et al.) 13 November 2008 see page 19 paragraph 3 – page 22 paragraph 2	1-10, 12, 14, 16, 18-30, 35-43, 48
Y	see page 19 paragraph 3 – page 22 paragraph 2	11, 13, 15, 17, 31-34, 44-47
Y	WO 2003/089906 A2 (UNIVERSITY OF FLORIDA) 30 October 2003 SEQ ID NO: 2 is 100% identical to SEQ ID NO: 13	15, 32, 45
Y	US 2006/0160121 A1 (MOUNTS et al.) 20 July 2006 SEQ ID NO: 1058943 is 100% identical to SEQ ID NO: 14	13, 31, 44
Y	US 2007/0048756 A1 (MEI et al.) 01 March 2007 SEQ ID NO: 246607 is 100% identical to SEQ ID NO: 2	11, 33, 46
Y	GenBank Accession No. FJ462451 published 17 December 2008 Sequence is identical to SEQ ID NO: 16 but for a single nucleotide addition	17, 34, 47

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/SG2012/000399	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
WO 2001/073123 A2	04 Oct 2001	AU 774593 B2	01 Jul 2004
		AU 784040 B2	19 Jan 2006
		AU 3059302 A	18 Jun 2002
		AU 3279501 A	24 Jul 2001
		AU 4043497 A	20 Feb 1998
		AU 5520301 A	08 Oct 2001
		AU 5637800 A	31 Jan 2001
		AU 8124801 A	13 Mar 2002
		AU 2002363062 B2	22 Mar 2007
		AU 2004254367 A1	13 Jan 2005
		AU 2004254367 B2	19 Jun 2008
		AU 2005325273 A1	27 Jul 2006
		AU 2005325273 B2	02 Jul 2009
		AU 2006200261 A1	09 Feb 2006
		AU 2006200274 A1	09 Feb 2006
		AU 2010202492 A1	08 Jul 2010
		CA 2262018 A1	05 Feb 1998
		CA 2376623 A1	04 Jan 2001
		CA 2396113 A1	19 Jul 2001
		CA 2402955 A1	04 Oct 2001
		CA 2418502 A1	07 Mar 2002
		CA 2463323 A1	01 May 2003
		CA 2529898 A1	13 Jan 2005
		CA 2565166 A1	27 Jul 2006
		CN 101001960 A	18 Jul 2007
		CN 101198707 A	11 Jun 2008
		EP 0918885 A1	02 Jun 1999
		EP 0918885 B1	11 Apr 2007
		EP 1198591 A1	24 Apr 2002
		EP 1198591 B1	16 Mar 2011
		EP 1294930 A2	26 Mar 2003
		EP 1294930 B1	30 Mar 2011
		EP 1301625 A2	16 Apr 2003
		EP 1301625 B1	03 Nov 2010
		EP 1356109 A2	29 Oct 2003
		EP 1362121 A2	19 Nov 2003

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/SG2012/000399	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		EP 1379693 A2	14 Jan 2004
		EP 1379693 B1	20 May 2009
		EP 1478774 A2	24 Nov 2004
		EP 1649055 A2	26 Apr 2006
		EP 1649055 B1	20 May 2009
		EP 1747295 A2	31 Jan 2007
		EP 1747295 B1	11 Jan 2012
		EP 1818417 A2	15 Aug 2007
		JP 2005514900 A	26 May 2005
		JP 4146239 B2	10 Sep 2008
		JP 2000516460 A	12 Dec 2000
		JP 4245664 B2	25 Mar 2009
		JP 2005525084 A	25 Aug 2005
		JP 4347049 B2	21 Oct 2009
		JP 2003503699 A	28 Jan 2003
		JP 2004194669 A	15 Jul 2004
		JP 2004501340 A	15 Jan 2004
		JP 2004515208 A	27 May 2004
		JP 2004525607 A	26 Aug 2004
		JP 2006288406 A	26 Oct 2006
		JP 2007525970 A	13 Sep 2007
		JP 2007537450 A	20 Dec 2007
		JP 2008000143 A	10 Jan 2008
		JP 2008029351 A	14 Feb 2008
		JP 2008067711 A	27 Mar 2008
		US 6361944 B1	26 Mar 2002
		US 6417340 B1	09 Jul 2002
		US 6495324 B1	17 Dec 2002
		US 6506564 B1	14 Jan 2003
		US 2002146720 A1	10 Oct 2002
		US 6582921 B2	24 Jun 2003
		US 2002182611 A1	05 Dec 2002
		US 6610491 B2	26 Aug 2003
		US 2003059777 A1	27 Mar 2003
		US 6645721 B2	11 Nov 2003
		US 2002164605 A1	07 Nov 2002

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)

INTERNATIONAL SEARCH REPORT	International application No.
Information on patent family members	PCT/SG2012/000399

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		US 6673548 B2	06 Jan 2004
		US 2002155459 A1	24 Oct 2002
		US 6677122 B2	13 Jan 2004
		US 2002182613 A1	05 Dec 2002
		US 6682895 B2	27 Jan 2004
		US 2003049631 A1	13 Mar 2003
		US 6709825 B2	23 Mar 2004
		US 2002155462 A1	24 Oct 2002
		US 6720147 B2	13 Apr 2004
		US 2002127574 A1	12 Sep 2002
		US 6720411 B2	13 Apr 2004
		US 2002137072 A1	26 Sep 2002
		US 6730269 B2	04 May 2004
		US 2002155458 A1	24 Oct 2002
		US 6740491 B2	25 May 2004
		US 2003022169 A1	30 Jan 2003
		US 6750016 B2	15 Jun 2004
		US 2003049630 A1	13 Mar 2003
		US 6759199 B2	06 Jul 2004
		US 2002155442 A1	24 Oct 2002
		US 6767702 B2	27 Jul 2004
		US 2002137058 A1	26 Sep 2002
		US 6773884 B2	10 Aug 2004
		US 2003044805 A1	06 Mar 2003
		US 6777186 B2	17 Aug 2004
		US 6812334 B1	02 Nov 2004
		US 2003148282 A1	07 Aug 2003
		US 6818753 B2	16 Nov 2004
		US 2003143538 A1	31 Jul 2003
		US 6828432 B2	07 Dec 2004
		US 2002160381 A1	31 Oct 2002
		US 6861221 B2	01 Mar 2005
		US 2002137070 A1	26 Sep 2002
		US 6878814 B2	12 Apr 2005
		US 2004219520 A1	04 Nov 2004
		US 6902895 B2	07 Jun 2005

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/SG2012/000399

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		US 2003124528 A1	03 Jul 2003
		US 6903207 B2	07 Jun 2005
		US 2003180783 A1	25 Sep 2003
		US 6962786 B2	08 Nov 2005
		US 2002155461 A1	24 Oct 2002
		US 6969761 B2	29 Nov 2005
		US 2002192687 A1	19 Dec 2002
		US 6974669 B2	13 Dec 2005
		US 2003087242 A1	08 May 2003
		US 6984491 B2	10 Jan 2006
		US 2003068622 A1	10 Apr 2003
		US 6986989 B2	17 Jan 2006
		US 7098320 B1	29 Aug 2006
		US 2003207296 A1	06 Nov 2003
		US 7169556 B2	30 Jan 2007
		US 2004072231 A1	15 Apr 2004
		US 7208587 B2	24 Apr 2007
		US 2004110220 A1	10 Jun 2004
		US 7250499 B2	31 Jul 2007
		US 2002137071 A1	26 Sep 2002
		US 7259252 B2	21 Aug 2007
		US 2006051798 A1	09 Mar 2006
		US 7323309 B2	29 Jan 2008
		US 2009325812 A1	31 Dec 2009
		US 8323888 B2	04 Dec 2012
		US 2002172953 A1	21 Nov 2002
		US 2003054358 A1	20 Mar 2003
		US 2005037397 A1	17 Feb 2005
		US 2006040286 A1	23 Feb 2006
		US 2006068378 A1	30 Mar 2006
		US 2010081134 A1	01 Apr 2010
		WO 0100876 A1	04 Jan 2001
		WO 0151665 A2	19 Jul 2001
		WO 0173123 A2	04 Oct 2001
		WO 0173123 B1	04 Mar 2004
		WO 0218643 A2	07 Mar 2002

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/SG2012/000399	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		WO 0246472 A2	13 Jun 2002
		WO 9804740 A1	05 Feb 1998
		WO 02079490 A2	10 Oct 2002
		WO 03035829 A2	01 May 2003
		WO 2005003394 A2	13 Jan 2005
		WO 2006078289 A2	27 Jul 2006
WO 2008/135929 A2	13 Nov 2008	EP 2145023 A2	20 Jan 2010
		PT 103730 A	04 Nov 2008
		US 2010075335 A1	25 Mar 2010
		WO 2008135929 A2	13 Nov 2008
WO 2003/089906 A2	30 Oct 2003	AU 2003234196 A1	03 Nov 2003
		CA 2482611 A1	30 Oct 2003
		CN 1662815 A	31 Aug 2005
		EP 1499895 A2	26 Jan 2005
		EP 1499895 B1	07 May 2008
		HK 1075698 A1	06 Feb 2009
		JP 2005523027 A	04 Aug 2005
		JP 4381826 B2	09 Dec 2009
		RU 2004133894 A	20 Apr 2005
		US 2004067503 A1	08 Apr 2004
		US 7524630 B2	28 Apr 2009
		WO 03089906 A2	30 Oct 2003
US 2006/0160121 A1	20 Jul 2006	AU 2005335216 A1	15 Feb 2007
		CA 2582137 A1	15 Feb 2007
		EP 1817432 A2	15 Aug 2007
		US 2006160121 A1	20 Jul 2006
		WO 2007018563 A2	15 Feb 2007
US 2007/0048756 A1	01 Mar 2007	US 2007048756 A1	01 Mar 2007
End of Annex			
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			